Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date

Peacock, Gina F; Sauvageot, Jurgita; Addo, Richard T

Abstract

Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date

Author(s): Peacock Gina F, Sauvageot Jurgita, Addo Richard T

Issue: Jul/Aug 2014 - Volume 18, Number 4

View All Articles in Issue

Page(s): 348-350

Download in electronic PDF format for $75

Note: Electronic version includes errata or revisions.

Abstract

Previous reports indicate that pharmacists are assigning a wide variety of beyond-use dates to extemporaneously compounded medications in topical Pluronic lecithin organogel. The objective of this study was to evaluate the stability of ketoprofen in Pluronic lecithin organogel over a period of six months and to determine an appropriate beyond-use date for this formulation. A stability-indicating high-performance liquid chromatography method for ketoprofen in Pluronic lecithin organogel was validated in our laboratory. Samples of the formulation were analyzed by high-performance liquid chromatography at 0, 7, 14, 21, 28, 45, 60, 90, and 180 days. At each time point, the average concentration and average percent of initial concentration were calculated. The beyond-use date was determined as the time period that the samples were physically stable and maintained at least 90% of the initial concentration. Ketoprofen in Pluronic lecithin organogel was chemically and physically stable for six months when stored at room temperature and protected from light. Therefore, a beyond-use date of six months is appropriate for this preparation.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2014 Pg. 348-350	Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita, Addo Richard T
Jul/Aug 2014 Pg. 345-347	Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita
May/Jun 2014 Pg. 253-255	Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita
May/Jun 2014 Pg. 256-261	Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery Author(s): Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
Jan/Feb 2021 Pg. 73-81	Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Author(s): Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
Nov/Dec 2010 Pg. 522-525	Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date Author(s): Pignato Alyssa, Pankaskie Marvin, Birnie Christine
May/Jun 2012 Pg. 248-252	In Vitro Percutaneous Absorption of Ketoprofen and Testosterone: Comparison of Pluronic Lecithin Organogel vs. Pentravan Cream Author(s): Lehman Paul A, Raney Sam G
Sep/Oct 2012 Pg. 428-430	Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date Author(s): Peacock Gina F, Sauvageot Jurgita
Jan/Feb 2022 Pg. 65-71	Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management Author(s): Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
May/Jun 2013 Pg. 247-253	Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel Author(s): Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
Jan/Feb 2016 Pg. 81-85	Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita, Hill Ashley, Killian Alyssa
Mar/Apr 2017 Pg. 164-170	Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs Author(s): Gorman Gregory, Sokom Simara, Coward Lori, Arnold John J
May/Jun 2005 Pg. 242-246	Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study Author(s): Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
Jul/Aug 2018 Pg. 319	Ketoprofen 10% in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
Nov/Dec 2010 Pg. 513	Baclofen 5%, Capcaicin 0.075%, Ketoprofen 10%, and Tetracaine 2% in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
Nov/Dec 2012 Pg. 471-474	Beyond-use Date: Establishment and Maintenance Author(s): Osteen Richard
Jan/Feb 2019 Pg. 52	Ketoprofen 10% in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
Mar/Apr 2019 Pg. 150	Ketoprofen 10% in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
Nov/Dec 2010 Pg. 512	Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
May/Jun 2011 Pg. 245	Ketoprofen 10%, Ibuprofen 10%, Cyclobenzaprine Hydrochloride 2%, and Piroxicam 2% in Pluronic Lecithin Organogel Gel Author(s): Allen Loyd V Jr